drugset / Trial / NCT05358249
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Timeline
- Start
- 2022-10-24
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Opnurasib | Small molecule | — | Oral |
| Subject | Ribociclib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |